PPCB · Propanc Biopharma, Inc.
$1.40
+0.05 (+3.70%)
At close · Aug 31
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“It is management's opinion that these conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of at least twelve months from the issue date of this Quarterly Report.”View the 10-Q filed May 14, 2026
Market Cap
$3.08M
Shares
2.28M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$58.92M
-3136.6%
FY2025
Diluted EPS
-$371.25
+99%
FY2025
Operating Cash Flow
-$405.17K
+56.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $32.1K | — | — | — | — | — | — | $28.06K | $30.52K | $28.99K | — | — | — | — | — | — | — | — | |
| $303.34K | $223.72K | $248.1K | $247.92K | $256.05K | $230.96K | $179.99K | $260.34K | $1.83M | $971.77K | $1.45M | $134.32K | $8168 | $12.34K | $5279 | $385.78K | — | — | |
| $18.03M | $57.03M | $1.25M | $1.5M | $1.71M | $1.55M | $3.28M | $2.33M | $2.1M | $4.74M | $5.43M | $1.57M | $742.04K | $1.34M | $11.57M | $1.84M | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $4062 | $1792 | $1857 | — | — | |
| $18.37M | $57.28M | $1.54M | $1.78M | $1.99M | $1.81M | $3.49M | $2.61M | $3.96M | $5.74M | $6.9M | $1.71M | $761.22K | $1.36M | $11.59M | $2.24M | — | — | |
| -$18.37M | -$57.28M | -$1.54M | -$1.78M | -$1.99M | -$1.81M | -$3.49M | -$2.61M | -$3.96M | -$5.74M | -$6.9M | -$1.71M | -$761.22K | -$1.36M | -$11.59M | -$2.24M | — | — | |
| $657.42K | $563.76K | $665.84K | $532.82K | $568.8K | $449.46K | $1.75M | $1.31M | $2.79M | $3.2M | $4.49M | $1.32M | $93.15K | $5465 | $2967 | — | — | — | |
| — | — | — | — | $5613 | $1 | $946 | $31 | $87 | $685 | $2027 | $33 | $18 | $0 | $141 | $439 | — | — | |
| $12.84K | -$1.65M | -$413.61K | -$1.01M | -$722.19K | -$327.22K | -$1.38M | -$3.26M | -$3.26M | -$2.43M | -$2.59M | -$1.78M | -$116.61K | -$141.2K | -$18.53K | -$1192 | — | — | |
| -$18.36M | -$58.92M | -$1.95M | -$2.79M | -$2.71M | -$2.14M | -$4.88M | -$5.76M | -$7.04M | — | — | — | — | — | — | — | — | — | |
| — | — | -$129.13K | -$129.84K | -$54.98K | -$113.42K | -$134.73K | -$115.44K | -$179.31K | -$305.67K | -$72.54K | -$77.47K | -$48.27K | -$60.46K | -$173.93K | -$84.58K | — | — | |
| -$18.36M | -$58.92M | -$1.82M | -$2.66M | -$2.66M | -$2.03M | -$4.74M | -$5.76M | -$7.04M | -$7.87M | -$9.41M | -$3.41M | -$829.56K | -$1.44M | -$11.43M | -$2.15M | -$842.49K | -$443.85K | |
| — | -$58.92M | -$2.01M | -$3.13M | -$3.36M | -$2.42M | -$4.74M | — | — | — | — | — | — | — | — | — | — | — | |
| -$19.52M | -$58.87M | -$2.04M | -$3.07M | -$3.21M | -$2.6M | -$4.54M | -$5.05M | -$6.54M | -$8.14M | -$9.38M | -$3.01M | -$887.84K | -$1.33M | -$11.67M | -$2.17M | — | — | |
| USD/shares | $1,621.99 | -$371.25 | -$35,513.25 | -$90.00 | -$2,461.50 | -$40.00 | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | $1,621.99 | -$371.25 | -$35,513.25 | -$90.00 | -$2,461.50 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 158.73K | 56.68 | 34.78K | 1364.38 | 60.65K | 492.68 | 10.4988 | 0.7876 | 70.1706 | 38.9641 | 3552.6699 | 1447.0111 | 1447.3106 | — | — | — | — |
| shares | — | 158.73K | 56.68 | 34.78K | 1364.38 | 60.65K | 492.68 | 10.4988 | 0.7876 | 70.1706 | 38.9641 | 3552.6699 | 1447.0111 | 1447.3106 | — | — | — | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.60×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 124 similar-size Biotechnology companies (of 508 listed).